Table 4. Association between clinical and pathologic factors, tumor MMR status and overall and EC-specific survival.
| Cases | Overall survival HR (95% CI) | EC-specific survival HR (95% CI) | ||
|---|---|---|---|---|
| All cases (n=728)* | ||||
| Age (continuous) | 1.06 (1.04–1.08) | 1.05 (1.03–1.08) | ||
| Stage | ||||
| I | 1.00 | |||
| II | 1.45 (0.74–2.90) | 1.24 (0.53–2.87) | ||
| III–IV | 3.28 (2.00–5.38) | 3.21 (1.86–5.52) | ||
| Histologic group | ||||
| Endometrioid grade 1 and 2 | 1.00 | |||
| Endometrioid grade 3 | 2.76 (1.58–4.81) | 4.20 (2.15–8.19) | ||
| Serous/clear cell/carcinosarcoma | 2.32 (1.42–3.80) | 3.44 (1.86–6.37) | ||
| Lymphovascular space involvement | ||||
| No/unknown | 1.00 | |||
| Yes | 1.68 (1.10–2.57) | 2.11 (1.26–3.51) | ||
| Adjuvant therapy† | ||||
| No | 1.00 | |||
| Yes | 1.03 (0.61–1.75) | 1.35 (0.69–2.65) | ||
| MMR status | ||||
| MMR-proficient | 1.00 | |||
| Somatic MMR-deficient | 0.93 (0.60–1.43) | 0.97 (0.59–1.59) | ||
| Germline MMR-deficient | 0.37 (0.05–2.72) | Not applicable‡ | ||
| Endometrioid cases only (n=598)∥ | ||||
| MMR status | ||||
| MMR-proficient | 1.00 | 1.00 | ||
| Somatic MMR-deficient | 1.50 (0.91–2.47) | 2.18 (1.19–4.01) | ||
| Germline MMR-deficient | 0.46 (0.06–3.52) | Not applicable‡ | ||
CI, confidence interval; EC, endometrial cancer; HR, hazard ratio; MMR, DNA mismatch repair.
*Adjusted for age (continuous), stage, histologic group, lymphovascular space involvement, adjuvant therapy; †Adjuvant therapy = brachytherapy or radiotherapy or chemotherapy; ‡None of the pathogenic variant carrier cases died from EC; ∥Adjusted for age (continuous), stage, grade, lymphovascular space involvement, adjuvant therapy.